To evaluate the efficacy of injecting platelet rich plasma in osteoarthritis knee and its relation with MAT2B gene

Efficacy Of Intra-Articular Injection Of Platelet Rich Plasma And The Modulation Of mRNA Expression Of MAT2B Gene In Patients With Early Stage Osteoarthritis Knee:A Prospective Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/02/023376

Enrollment

Registered

2020-02-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M171- Unilateral primary osteoarthritisof knee

Interventions

Intervention1: Injection Of Platelet Rich Plasma In Patients Of Primary Osteoarthritis Knee In One With More Severe Clinico-radiological Disease: Injection Of Platelet Rich Plasma containing 3-4 ml Of

Eligibility

Inclusion criteria

Inclusion criteria: 1)Age >45 years and 2)Diagnosed case of osteoarthritis knee based on clinico- radiological diagnosis 3)In case of bilateral symptoms side with more significant symptom receives treatment 4)NRS score of >=4/10 over minimum 3 months 5)Grade 1, 2, 3 of Kellgren and Lawrence system of classification of severity of knee OA(28) 6)Patients who have tried atleast 3 months of non-invasive conservative treatment including lifestyle modification before the beginning of therapy

Exclusion criteria

Exclusion criteria: 1)Diagnosis of secondary OA (Post-traumatic, post-surgical and post-inflammatory osteoarthritis) 2)Recent intra-articular injection of corticosteroids within last 3 months and prior treatment with hyaluronic acid in past 6 months 3)Anemia (Hb < 10gm%)

Design outcomes

Primary

Measure	Time frame
1)Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain score, stiffness score, physical function score and WOMAC total score at various designated intervals 2)NRS pain score at various designated intervalsTimepoint: baseline and at the end of 1st week, 2nd week, 4th week, 8th week and 12th week	—

Secondary

Measure	Time frame
1)Lequesne scores following implementation of injection at various designated intervals 2)Neuropathic component of pain using NPSI scores at various designated intervals 3)The quality of life QoL usng SF-12 questionnaire scores at various designated intervals 4)Modulation in mRNA expression of MAT2B genes at baseline and after 12 weeks following intra-articular treatment.Timepoint: baseline and at the end of 1st week, 2nd week, 4th week,6th week,8th week and 12th week.	—

Measure

Time frame

1)Lequesne scores following implementation of injection at various designated intervals 2)Neuropathic component of pain using NPSI scores at various designated intervals 3)The quality of life QoL usng SF-12 questionnaire scores at various designated intervals 4)Modulation in mRNA expression of MAT2B genes at baseline and after 12 weeks following intra-articular treatment.Timepoint: baseline and at the end of 1st week, 2nd week, 4th week,6th week,8th week and 12th week.

—

Countries

India

Contacts

Public ContactParul Gupta

University College Of Medical Sciences and GTB Hospital

profashoksaxena2@gmail.com9810431367

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026